Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy
Description
Bleomycin has been used as a carrier for several radioisotopes; however, its potential for clinical use has been limited either by the in vivo stability of the complexes or the half-life of the isotope used. The chemical, biological, and radiological properties of 105Rhodium appear to make it an ideal choice for targeted radiotherapy. The synthesis and purification of a hereto unreported 105Rhodium-bleomycin (105Rh-BLM) complex is described. The stability of this complex in plasma is sufficient to allow targeted delivery of the radioisotope. 57Cobalt-bleomycin was studied under identical conditions for comparative purposes. The suitability of 105Rh-BLM for targeted therapy, which appears to be limited by the renal clearance of this agent, is discussed
Additional details
Identifiers
- PII
- S0969805198001097;
Publishing Information
- Journal Title
- Nuclear Medicine and Biology
- Journal Volume
- 26
- Journal Issue
- 4
- Journal Page Range
- p. 421-430
- ISSN
- 0969-8051
- CODEN
- NMBIEO
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 33025396
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOLOGICAL HALF-LIFE; CHEMICAL PREPARATION; COBALT 57; LABELLED COMPOUNDS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RENAL CLEARANCE; RHODIUM 105
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; CLEARANCE; COBALT ISOTOPES; DAYS LIVING RADIOISOTOPES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; EXCRETION; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; MATERIALS; MEDICINE; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; RHODIUM ISOTOPES; SECONDS LIVING RADIOISOTOPES; SYNTHESIS; THERAPY
Optional Information
- Copyright
- Copyright (c) 1999 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.